Table 3.
Demographic information on 227 patients with K. pneumoniae bacteraemia based on ciprofloxacin MIC
| MIC ≥0.12 mg/L (n = 24), n (%) or mean ± SD | MIC ≤0.06 mg/L (n = 203), n (%) or mean ± SD | P value | |
|---|---|---|---|
| Patient location (place where bacteraemia was detected) | 0.07 | ||
| emergency department | 9 (37.5) | 126 (62.1) | |
| hospital-acquired infection | |||
| ward | 10 (41.7) | 50 (24.6) | |
| intensive care unit | 5 (20.8) | 27 (13.3) | |
| Age (years) | 68.4 ± 3.1 | 60.7 ± 1.1 | 0.02 |
| Sex (male) | 12 (50.0) | 135 (66.5) | 0.11 |
| Pittsburgh bacteraemia score | 4.5 ± 1.0 | 4.2 ± 0.3 | 0.77 |
| Time to positivity of culture (hours)a | 13.7 ± 2.7 | 13.1 ± 1.1 | 0.99 |
| Underlying illness/condition | |||
| diabetes mellitus | 11 (45.8) | 77 (37.9) | 0.45 |
| cirrhosis | 1 (4.2) | 32 (15.8) | 0.13 |
| end-stage renal disease | 2 (8.3) | 8 (3.9) | 0.29 |
| stroke | 5 (20.8) | 23 (11.3) | 0.18 |
| chronic heart disease | 3 (12.5) | 42 (20.7) | 0.43 |
| bedridden status | 10 (41.7) | 25 (12.3) | <0.001 |
| active malignancy | 5 (20.8) | 34 (16.7) | 0.62 |
| surgery within 3 months | 10 (41.7) | 47 (23.2) | 0.048 |
| Infection focus | |||
| primary bacteraemia | 5 (20.8) | 57 (28.1) | 0.45 |
| pneumonia | 7 (29.2) | 34 (16.7) | 0.14 |
| urinary tract infection | 5 (20.8) | 31 (15.3) | 0.48 |
| biliary tract infection | 3 (12.5) | 28 (13.8) | 1.00 |
| liver abscess | 2 (8.3) | 28 (13.8) | 0.75 |
| intra-abdominal infection | 1 (4.2) | 13 (6.4) | 1.00 |
| catheter-related bacteraemia | 1 (4.2) | 5 (2.5) | 0.49 |
| soft tissue infection | 0 (0) | 3 (1.5) | 1.00 |
| meningitis | 0 (0) | 3 (1.5) | 1.00 |
| other | 0 (0) | 1 (0.5) | 1.00 |
| Outcome | |||
| 14 day mortality | 6 (25.0) | 44 (21.7) | 0.71 |
| in-hospital mortality | 10 (41.7) | 63 (31.0) | 0.29 |
| Bacterial serotype | |||
| K1 | 2 (8.3) | 39 (19.2) | 0.27 |
| K2 | 1 (4.2) | 36 (17.7) | 0.39 |
| non-K1/K2 | 21 (87.5) | 128 (63.1) | 0.11 |
| ESBL phenotype | 4 (16.7) | 0 (0) | <0.001 |
| Quinolone use within 1 year | 6 (25.0) | 13 (6.4) | 0.002 |
| Quinolone use within 270 days | 6 (25.0) | 12 (5.9) | 0.001 |
| Quinolone use within 180 days | 6 (25.0) | 10 (4.9) | <0.001 |
| Quinolone use within 90 days | 6 (25.0) | 6 (3.0) | <0.001 |
| Other antibiotic use within 1 year | 12 (50.0) | 81 (39.9) | 0.34 |
| Other antibiotic use within 270 days | 12 (50.0) | 78 (38.4) | 0.27 |
| Other antibiotic use within 180 days | 10 (41.7) | 74 (36.5) | 0.62 |
| Other antibiotic use within 90 days | 9 (37.5) | 66 (32.5) | 0.62 |
Categories with P values <0.05 appear in bold.
aTime to positivity of culture was acquired using the BACTEC 9240 automated detection blood culture system (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA), which defines time to positivity as the time from the start of incubation to the start of the alert signal indicating positive blood culture.